Your browser doesn't support javascript.
loading
Mega-analysis of association between obesity and cortical morphology in bipolar disorders: ENIGMA study in 2832 participants.
McWhinney, Sean R; Abé, Christoph; Alda, Martin; Benedetti, Francesco; Bøen, Erlend; Del Mar Bonnin, Caterina; Borgers, Tiana; Brosch, Katharina; Canales-Rodríguez, Erick J; Cannon, Dara M; Dannlowski, Udo; Diaz-Zuluaga, Ana M; Dietze, Lorielle M F; Elvsåshagen, Torbjørn; Eyler, Lisa T; Fullerton, Janice M; Goikolea, Jose M; Goltermann, Janik; Grotegerd, Dominik; Haarman, Bartholomeus C M; Hahn, Tim; Howells, Fleur M; Ingvar, Martin; Jahanshad, Neda; Kircher, Tilo T J; Krug, Axel; Kuplicki, Rayus T; Landén, Mikael; Lemke, Hannah; Liberg, Benny; Lopez-Jaramillo, Carlos; Malt, Ulrik F; Martyn, Fiona M; Mazza, Elena; McDonald, Colm; McPhilemy, Genevieve; Meier, Sandra; Meinert, Susanne; Meller, Tina; Melloni, Elisa M T; Mitchell, Philip B; Nabulsi, Leila; Nenadic, Igor; Opel, Nils; Ophoff, Roel A; Overs, Bronwyn J; Pfarr, Julia-Katharina; Pineda-Zapata, Julian A; Pomarol-Clotet, Edith; Raduà, Joaquim.
Afiliação
  • McWhinney SR; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • Abé C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Alda M; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • Benedetti F; Vita-Salute San Raffaele University, Milan, Italy.
  • Bøen E; Division of Neuroscience, Psychiatry and Psychobiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Del Mar Bonnin C; Unit for Psychosomatics/CL Outpatient Clinic for Adults, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Borgers T; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • Brosch K; Department of Psychiatry, University of Münster, Münster, Germany.
  • Canales-Rodríguez EJ; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
  • Cannon DM; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.
  • Dannlowski U; Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland.
  • Diaz-Zuluaga AM; Department of Psychiatry, University of Münster, Münster, Germany.
  • Dietze LMF; Research Group in Psychiatry GIPSI, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia.
  • Elvsåshagen T; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • Eyler LT; Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Fullerton JM; Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
  • Goikolea JM; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Goltermann J; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
  • Grotegerd D; Desert-Pacific MIRECC, VA San Diego Healthcare, San Diego, CA, USA.
  • Haarman BCM; Neuroscience Research Australia, Randwick, NSW, Australia.
  • Hahn T; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Howells FM; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • Ingvar M; Department of Psychiatry, University of Münster, Münster, Germany.
  • Jahanshad N; Department of Psychiatry, University of Münster, Münster, Germany.
  • Kircher TTJ; Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Krug A; Department of Psychiatry, University of Münster, Münster, Germany.
  • Kuplicki RT; Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • Landén M; Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
  • Lemke H; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Liberg B; Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.
  • Lopez-Jaramillo C; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
  • Malt UF; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
  • Martyn FM; Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.
  • Mazza E; Laureate Institute for Brain Research, Tulsa, OK, USA.
  • McDonald C; Department of Neuroscience and Physiology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.
  • McPhilemy G; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Meier S; Department of Psychiatry, University of Münster, Münster, Germany.
  • Meinert S; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Meller T; Research Group in Psychiatry GIPSI, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia.
  • Melloni EMT; Unit for Psychosomatics/CL Outpatient Clinic for Adults, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
  • Mitchell PB; Department of Neurology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Nabulsi L; Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland.
  • Nenadic I; Vita-Salute San Raffaele University, Milan, Italy.
  • Opel N; Division of Neuroscience, Psychiatry and Psychobiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ophoff RA; Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland.
  • Overs BJ; Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland.
  • Pfarr JK; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • Pineda-Zapata JA; Department of Psychiatry, University of Münster, Münster, Germany.
  • Pomarol-Clotet E; Institute for Translational Neuroscience, University of Münster, Münster, Germany.
  • Raduà J; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
Psychol Med ; : 1-11, 2023 Feb 27.
Article em En | MEDLINE | ID: mdl-36846964
ABSTRACT

BACKGROUND:

Obesity is highly prevalent and disabling, especially in individuals with severe mental illness including bipolar disorders (BD). The brain is a target organ for both obesity and BD. Yet, we do not understand how cortical brain alterations in BD and obesity interact.

METHODS:

We obtained body mass index (BMI) and MRI-derived regional cortical thickness, surface area from 1231 BD and 1601 control individuals from 13 countries within the ENIGMA-BD Working Group. We jointly modeled the statistical effects of BD and BMI on brain structure using mixed effects and tested for interaction and mediation. We also investigated the impact of medications on the BMI-related associations.

RESULTS:

BMI and BD additively impacted the structure of many of the same brain regions. Both BMI and BD were negatively associated with cortical thickness, but not surface area. In most regions the number of jointly used psychiatric medication classes remained associated with lower cortical thickness when controlling for BMI. In a single region, fusiform gyrus, about a third of the negative association between number of jointly used psychiatric medications and cortical thickness was mediated by association between the number of medications and higher BMI.

CONCLUSIONS:

We confirmed consistent associations between higher BMI and lower cortical thickness, but not surface area, across the cerebral mantle, in regions which were also associated with BD. Higher BMI in people with BD indicated more pronounced brain alterations. BMI is important for understanding the neuroanatomical changes in BD and the effects of psychiatric medications on the brain.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá